The Regulation Role of Ferroptosis Mechanism of Anti-Cancer Drugs and Noncoding RNAs


Ensoy M., Bumin Z. S., Jama H. A., CANSARAN DUMAN D.

Current Medicinal Chemistry, cilt.30, sa.14, ss.1638-1656, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 14
  • Basım Tarihi: 2023
  • Doi Numarası: 10.2174/0929867329666220629154418
  • Dergi Adı: Current Medicinal Chemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1638-1656
  • Anahtar Kelimeler: anti-cancer drugs, cell death, Ferroptosis, miRNA, non-coding RNAs (ncRNAs), Sorafenib
  • Ankara Üniversitesi Adresli: Evet

Özet

Ferroptosis is a recently discovered type of cell death caused by the accumulation of iron-dependent lipid peroxides and reactive oxygen species that differs significantly from other cell death pathways such as apoptosis, necrosis, and autophagy. Ferroptosis is essential in developing and treating ischemia-reperfusion injury, neurological diseases, cancer, and other diseases. The ferroptosis mechanism, which can be induced by reagents like erastin and glutamate, and suppressed by antioxidants such as vitamin E and deferoxamine (DFO) chelators, can be regulated at the epigenetic, transcriptional, post-transcriptional, and post-translational levels. A recent study has determined many non-coding RNAs (lncRNA, miRNA, circRNA) that modulate ferroptotic cell death in cancer cells. Furthermore, some anti-cancer drugs (Sorafenib, Sulfasalazine, Acetominofen, Lanperi-sone, etc.) used in pre-clinical and clinical applications have been shown to induce ferroptosis in various cancer types. However, in addition to the studies in the literature, it is necessary to define novel molecules & non-coding RNAs and determine their effects on the ferroptosis mechanism. Thus, it will be possible to develop effective and safe treatment options.